Addex Therapeutics Ltd (ADXN) - Net Assets
Based on the latest financial reports, Addex Therapeutics Ltd (ADXN) has net assets worth CHF3.29 Million CHF (≈ $4.16 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF4.76 Million ≈ $6.02 Million USD) and total liabilities (CHF1.47 Million ≈ $1.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Addex Therapeutics Ltd (ADXN) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF3.29 Million |
| % of Total Assets | 69.06% |
| Annual Growth Rate | -10.86% |
| 5-Year Change | -71.88% |
| 10-Year Change | 2078.29% |
| Growth Volatility | 655.83 |
Addex Therapeutics Ltd - Net Assets Trend (2006–2025)
This chart illustrates how Addex Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Addex Therapeutics Ltd worth.
Annual Net Assets for Addex Therapeutics Ltd (2006–2025)
The table below shows the annual net assets of Addex Therapeutics Ltd from 2006 to 2025. Also explore Addex Therapeutics Ltd equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CHF4.76 Million ≈ $6.02 Million |
-50.76% |
| 2024-12-31 | CHF9.67 Million ≈ $12.23 Million |
+744.27% |
| 2023-12-31 | CHF1.15 Million ≈ $1.45 Million |
-76.68% |
| 2022-12-31 | CHF4.91 Million ≈ $6.21 Million |
-70.98% |
| 2021-12-31 | CHF16.93 Million ≈ $21.41 Million |
+15.89% |
| 2020-12-31 | CHF14.61 Million ≈ $18.47 Million |
-42.76% |
| 2019-12-31 | CHF25.52 Million ≈ $32.27 Million |
-34.96% |
| 2018-12-31 | CHF39.24 Million ≈ $49.61 Million |
+2822.90% |
| 2017-12-31 | CHF1.34 Million ≈ $1.70 Million |
+514.17% |
| 2016-12-31 | CHF218.59K ≈ $276.36K |
-86.87% |
| 2015-12-31 | CHF1.66 Million ≈ $2.10 Million |
-29.05% |
| 2014-12-31 | CHF2.35 Million ≈ $2.97 Million |
-22.48% |
| 2013-12-31 | CHF3.03 Million ≈ $3.83 Million |
-81.43% |
| 2012-12-31 | CHF16.29 Million ≈ $20.60 Million |
-51.85% |
| 2011-12-31 | CHF33.84 Million ≈ $42.78 Million |
-47.47% |
| 2010-12-31 | CHF64.41 Million ≈ $81.44 Million |
-16.97% |
| 2009-12-31 | CHF77.58 Million ≈ $98.08 Million |
-34.80% |
| 2008-12-31 | CHF118.99 Million ≈ $150.44 Million |
-15.07% |
| 2007-12-31 | CHF140.11 Million ≈ $177.13 Million |
+231.40% |
| 2006-12-31 | CHF42.28 Million ≈ $53.45 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Addex Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 29565121100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CHF2.19 Million | 45.92% |
| Other Comprehensive Income | CHF96.38 Million | 2024.08% |
| Other Components | CHF266.29 Million | 5592.45% |
| Total Equity | CHF4.76 Million | 100.00% |
Addex Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Addex Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TwentyFour Select Monthly Income Fund Ltd
LSE:SMIF
|
$3.89 Million |
|
Cemtrex Inc
NASDAQ:CETX
|
$3.89 Million |
|
Intelligent Group Limited Ordinary Shares
NASDAQ:INTJ
|
$3.89 Million |
|
Trucknet Enterprise Ltd
TA:TRAN
|
$3.89 Million |
|
Groupe Airwell Société anonyme
PA:ALAIR
|
$3.89 Million |
|
Aldrich Resources Bhd
KLSE:0079
|
$3.89 Million |
|
G Capital Public Company Limited
BK:GCAP
|
$3.88 Million |
|
Keyang Electric Machinery Co Ltd
KO:012205
|
$3.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Addex Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,670,775 to 4,761,562, a change of -4,909,213 (-50.8%).
- Net loss of 6,729,000 reduced equity.
- Share repurchases of 28,850 reduced equity.
- New share issuances of 1,228,733 increased equity.
- Other comprehensive income increased equity by 694,435.
- Other factors decreased equity by 74,531.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF-6.73 Million | -141.32% |
| Share Repurchases | CHF28.85K | -0.61% |
| Share Issuances | CHF1.23 Million | +25.81% |
| Other Comprehensive Income | CHF694.43K | +14.58% |
| Other Changes | CHF-74.53K | -1.57% |
| Total Change | CHF- | -50.76% |
Book Value vs Market Value Analysis
This analysis compares Addex Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.52x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.52x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CHF8.43 | CHF0.02 | x |
| 2007-12-31 | CHF27.93 | CHF0.02 | x |
| 2008-12-31 | CHF20.74 | CHF0.02 | x |
| 2009-12-31 | CHF13.53 | CHF0.02 | x |
| 2010-12-31 | CHF10.89 | CHF0.02 | x |
| 2011-12-31 | CHF4.55 | CHF0.02 | x |
| 2012-12-31 | CHF2.06 | CHF0.02 | x |
| 2013-12-31 | CHF0.33 | CHF0.02 | x |
| 2014-12-31 | CHF0.23 | CHF0.02 | x |
| 2015-12-31 | CHF0.15 | CHF0.02 | x |
| 2016-12-31 | CHF0.02 | CHF0.02 | x |
| 2017-12-31 | CHF0.10 | CHF0.02 | x |
| 2018-12-31 | CHF1.68 | CHF0.02 | x |
| 2019-12-31 | CHF0.97 | CHF0.02 | x |
| 2020-12-31 | CHF0.55 | CHF0.02 | x |
| 2021-12-31 | CHF0.50 | CHF0.02 | x |
| 2022-12-31 | CHF0.11 | CHF0.02 | x |
| 2023-12-31 | CHF0.02 | CHF0.02 | x |
| 2024-12-31 | CHF0.10 | CHF0.02 | x |
| 2025-12-31 | CHF0.04 | CHF0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Addex Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -141.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3889.60%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.34x
- Recent ROE (-141.32%) is above the historical average (-230.16%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -48.60% | -433.53% | 0.10x | 1.10x | CHF-24.77 Million |
| 2007 | -25.04% | -7205.50% | 0.00x | 1.07x | CHF-49.10 Million |
| 2008 | -18.54% | -82.32% | 0.20x | 1.11x | CHF-33.97 Million |
| 2009 | -55.03% | -1043.62% | 0.05x | 1.14x | CHF-50.45 Million |
| 2010 | -52.23% | -1703.33% | 0.03x | 1.15x | CHF-40.09 Million |
| 2011 | -92.04% | -1102.95% | 0.06x | 1.29x | CHF-34.52 Million |
| 2012 | -165.85% | -22313.20% | 0.01x | 1.33x | CHF-28.65 Million |
| 2013 | -477.92% | -15760.49% | 0.02x | 1.94x | CHF-14.76 Million |
| 2014 | -75.66% | -2078.19% | 0.02x | 1.70x | CHF-2.01 Million |
| 2015 | -252.62% | -10432.03% | 0.01x | 1.74x | CHF-4.37 Million |
| 2016 | -1440.76% | -18174.08% | 0.01x | 7.70x | CHF-3.17 Million |
| 2017 | -244.35% | -656.22% | 0.16x | 2.28x | CHF-3.41 Million |
| 2018 | -4.19% | -27.21% | 0.14x | 1.08x | CHF-5.57 Million |
| 2019 | -57.91% | -534.98% | 0.08x | 1.29x | CHF-17.33 Million |
| 2020 | -88.01% | -355.92% | 0.18x | 1.38x | CHF-14.32 Million |
| 2021 | -91.05% | -528.58% | 0.13x | 1.33x | CHF-17.11 Million |
| 2022 | -423.46% | -1462.57% | 0.17x | 1.69x | CHF-21.30 Million |
| 2023 | -921.57% | -654.47% | 0.35x | 4.05x | CHF-10.67 Million |
| 2024 | 72.96% | 1720.75% | 0.04x | 1.10x | CHF6.09 Million |
| 2025 | -141.32% | -3889.60% | 0.03x | 1.34x | CHF-7.21 Million |
Industry Comparison
This section compares Addex Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $647,203,300
- Average return on equity (ROE) among peers: -32.90%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Addex Therapeutics Ltd (ADXN) | CHF3.29 Million | -48.60% | 0.45x | $3.89 Million |
| Bachem Holding AG (BANB) | $1.17 Billion | 8.61% | 0.18x | $5.42 Billion |
| BB Biotech AG (BION) | $3.90 Billion | 17.72% | 0.02x | $2.93 Billion |
| Bioversys AG (BIOV) | $10.68 Million | -175.24% | 2.27x | $160.82 Million |
| Basilea Pharmaceutica AG (BSLN) | $-92.96 Million | 0.00% | 0.00x | $686.09 Million |
| Idorsia Ltd (IDIA) | $657.62 Million | -58.76% | 1.14x | $1.03 Billion |
| MINDMAZE THERAPEUTICS HOLDING SA (MMTX) | $86.00K | -1.16% | 0.08x | $32.12 Million |
| Molecular Partners AG (MOLN) | $176.43 Million | -35.13% | 0.12x | $145.86 Million |
| Newron Pharmaceuticals SpA (NWRN) | $-11.13 Million | 0.00% | 0.00x | $243.84 Million |
| Relief Therapeutics Holding AG (RLF) | $14.30 Million | -52.18% | 0.39x | $36.33 Million |
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-in… Read more